Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005))

David S. Hong, Maria E. Cabanillas, Jennifer Jane Wheler, Aung Naing, Apostolia M. Tsimberidou, Lei Ye, Naifa L. Busaidy, Steven G. Waguespack, Mike Hernandez, Alder K. El Naggar, Savita Bidyasar, John Wright, Steven I. Sherman, Razelle Kurzrock

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005))'. Together they form a unique fingerprint.